Skip to content

Author

Fadhilla Resendryana Esthya

We have 3 of 3 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Towards Precision Therapy: A Systematic Review and Meta-Analysis of Targeted Therapy Effectiveness and Safety in Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) non-Philadelphia chromosome–positive (non-Ph+) is a major subtype of leukemia with high relapse rates and significant toxicity from conventional chemotherapy. This study evaluated the efficacy and safety of targeted therapy versus chemotherapy in non-Ph+ ALL. This systematic review an...

D. N. N. Karyana, Fadhilla Resendryana Esthya, I. N. Diarsa · 0 citations
Open access Aug 2026

Insulin Enhances the Viability of Doxorubicin-Exposed Luminal A Breast Cancer T-47D Cells

Insulin affects the viability of Luminal A breast cancer T-47D cells exposed to doxorubicin, indicating reduced cellular sensitivity to the cytotoxic effects of doxorubicin.

Fadhilla Resendryana Esthya, Novrita Padauleng, L. Prihatina · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.